Arndt Stahler

14PUBLICATIONS
72CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Molecular medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jan 05, 2026
Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer.

Julius Keyl, René Hosch, Fabian Hörst

|Nov 18, 2025
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.

Arndt Stahler, Dominik Paul Modest, Sebastian Stintzing

|Sep 04, 2025
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials.

Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto

|Aug 28, 2025
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials.

Alexej Ballhausen, Federica Morano, Arndt Stahler

|Jul 30, 2025
Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti-EGFR-Based Maintenance for RAS wt Metastatic CRC-The PanaMa (AIO KRK0212) Trial.

Alexej Ballhausen, Susanna Swoboda, David Horst

|Jan 30, 2024
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212).

Arndt Stahler, Andreas J Kind, Christine Sers

Pageof 3

Frequent Collaborators

11 joint publications

Sebastian Stintzing

10 joint publications

Dominik Paul Modest

7 joint publications

Annika Kurreck

6 joint publications

Volker Heinemann